---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-033541"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2025-09-02T23:59:59+00:00"
generated_at: "2026-05-17T09:07:37.618291+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Ionis reports positive Phase 3 results for olezarsen in sHTG: 72% triglyceride drop, 85% pancreatitis reduction

## Summary
- Olezarsen achieved 72% placebo-adjusted mean reduction in fasting triglycerides in Phase 3 CORE study (p<0.0001)
- Olezarsen reduced acute pancreatitis events by 85% (p=0.0002) in pooled analysis of CORE and CORE2 studies
- Over 90% of patients from CORE/CORE2 enrolled in open-label extension study
- Ionis plans to submit sNDA to FDA for olezarsen in sHTG by end of year

## SEC filing metadata
- accession: 0001140361-25-033541
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2025-09-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036125033541/0001140361-25-033541-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036125033541/ef20054942_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-033541
- JSON: https://secwatch.observer/filing/0001140361-25-033541.json
- Plain text: https://secwatch.observer/filing/0001140361-25-033541.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.